SCHEMBL4201391

SCHEMBL4201391

c1ccc(-n2ncc3cccnc32)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
HIF1A Q16665 2/20 0.49
DPP4 P27487 2/20 0.47
ALDH1A1 P00352 6/20 0.46
HSD17B10 Q99714 4/20 0.46
CYP1A2 P05177 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
EGFR P00533 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
PI4KA P42356 1/20 0.46
PI4K2B Q8TCG2 1/20 0.46
PI4K2A Q9BTU6 1/20 0.46
PI4KB Q9UBF8 1/20 0.46
CYP17A1 P05093 1/20 0.44
HTT P42858 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL10590166 0.88 KDM4E (0.77) KDM4EHIF1ADPP4ALDH1A1MEN1
Maleic Acid SCHEMBL10590159 0.88 KDM4E (0.77) KDM4EHIF1ADPP4ALDH1A1MEN1
SCHEMBL30117642 0.86 KDM4E (0.75) KDM4EALDH1A1HSD17B10CYP1A2MEN1
SCHEMBL7701732 0.84 KDM4E (0.73) KDM4EHIF1AALDH1A1HSD17B10CYP1A2
SCHEMBL29624191 0.84 KDM4E (0.73) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL10176225 0.80 KDM4E (0.67) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL29714856 0.80 KDM4E (0.67) KDM4EDPP4ALDH1A1CYP1A2CYP17A1
SCHEMBL5683198 0.80 KDM4E (0.67) KDM4EDPP4ALDH1A1CYP1A2CYP17A1
SCHEMBL9980902 0.78 KDM4E (0.63) KDM4EMEN1KMT2AHTTMAPT
SCHEMBL29624329 0.77 KDM4E (0.62) KDM4EHIF1AALDH1A1CYP17A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285629-A 5- [1,2, 4-Oxadiazole ] -6-oxygen-pyrazolopyridine derivative and preparation method and application thereof 中南大学 2025-01-10 CN claimed
CN-119285629-A 5- [1,2, 4-Oxadiazole ] -6-oxygen-pyrazolopyridine derivative and preparation method and application thereof 中南大学 2025-01-10 CN disclosed
US-9796711-B2 Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use ABBVIE S.Á.R.L. (LU) 2017-10-24 US disclosed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20070148185-A1 Novel therapeutic target for protozoal diseases VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2007-06-28 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed
EP-0338087-A1 FUSED PYRAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR MEDICINAL USE Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 KDM4E 3384/4885HIF1A 3778/4885DPP4 1311/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 KDM4E 3953/4885HIF1A 3856/4885DPP4 1956/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 KDM4E 3953/4885HIF1A 3856/4885DPP4 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.